Aeglea BioTherapeutics doses first patient in phase 1 trial of AEB1102
Aeglea BioTherapeutics announced the dosing of the first patient in a Phase 1 trial of AEB1102, a recombinant human enzyme designed to degrade the amino acid arginine, for the treatment of the hematological malignancies acute myeloid leukemia and myelodysplastic syndrome. August 29, 2016